Institutional
Kalehua Capital Management LLC
CIK 0002106181
$141.3M
Reported AUM
25
Positions
Q1 2026
Period
2026-05-15
Filed
Editorial summary
Summary for Kalehua Capital Management LLC · Q1 2026 is not yet generated. It will appear here after the next nightly run.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BOXX | EA SERIES TRUST | $117.62 | 0.02% | 3.99% | 17.39% | $25.4M | 17.96% | — | HELD |
| 2 | XFOR | X4 Pharmaceuticals Inc | $4.00 | 1.78% | 145.63% | -97.45% | $15.4M | 10.88% | — | HELD |
| 3 | SRZN | Surrozen Inc | $19.20 | -1.03% | 74.55% | -83.55% | $11.2M | 7.94% | — | HELD |
| 4 | MANE | VERADERMICS INC | $107.76 | -3.39% | 189.86% | 76.63% | $9.2M | 6.51% | — | HELD |
| 5 | RLAY | Relay Therapeutics Inc | $18.37 | 0.44% | 447.62% | -42.60% | $9.0M | 6.35% | — | HELD |
| 6 | SION | Sionna Therapeutics Inc | $44.81 | -3.74% | 168.82% | 334.85% | $7.9M | 5.59% | — | HELD |
| 7 | ACRS | ACLARIS THERAPEUTICS INC | $5.12 | -3.94% | 237.58% | -68.14% | $6.9M | 4.86% | — | HELD |
| 8 | IKT | Inhibikase Therapeutics Inc | $2.21 | -4.33% | 45.39% | -84.46% | $6.4M | 4.54% | — | HELD |
| 9 | ORKA | Oruka Therapeutics Inc | $88.07 | -2.63% | 547.57% | 341.62% | $5.8M | 4.11% | — | HELD |
| 10 | PHVS | Pharvaris NV | $32.62 | -3.05% | 66.05% | 64.49% | $5.6M | 3.97% | — | HELD |
| 11 | QURE | Uniqure NV | $40.07 | 9.30% | 189.56% | 36.74% | $4.8M | 3.37% | — | HELD |
| 12 | SEPN | Septerna Inc | $33.61 | -1.06% | 173.22% | 31.91% | $4.7M | 3.31% | — | HELD |
| 13 | CMPS | Compass Pathways PLC | $10.90 | 0.46% | 151.15% | -67.85% | $4.5M | 3.21% | — | HELD |
| 14 | LONA | LeonaBio Inc | $7.04 | 1.00% | 90.27% | -93.35% | $4.0M | 2.86% | — | HELD |
| 15 | DMRA | Damora Therapeutics Inc | $28.33 | -3.70% | 783.93% | -74.53% | $3.6M | 2.55% | — | HELD |
| 16 | GOSS | Gossamer Bio Inc | $0.21 | 0.98% | -89.67% | -97.92% | $3.4M | 2.38% | — | HELD |
| 17 | MLTX | MoonLake Immunotherapeutics | $18.38 | -1.76% | -64.83% | 88.36% | $3.3M | 2.32% | — | HELD |
| 18 | TYRA | Tyra Biosciences Inc | $31.11 | 0.74% | 197.78% | 37.92% | $2.9M | 2.02% | — | HELD |
| 19 | PEPG | PepGen Inc | $1.71 | -6.56% | 29.55% | -82.78% | $1.8M | 1.25% | — | HELD |
| 20 | TIL | Instil Bio Inc | $7.22 | -0.96% | -67.52% | -98.08% | $1.5M | 1.07% | — | HELD |
| 21 | TNYA | Tenaya Therapeutics Inc | $0.74 | -2.78% | 12.68% | -96.27% | $1.4M | 0.98% | — | HELD |
| 22 | KRRO | KORRO BIO INC | $10.07 | -4.10% | -27.29% | -97.39% | $1.2M | 0.88% | — | HELD |
| 23 | KLRS | Kalaris Therapeutics Inc | $3.40 | 1.80% | 26.39% | -99.23% | $782K | 0.55% | — | HELD |
| 24 | DMAC | DiaMedica Therapeutics Inc | $6.32 | -4.82% | 53.40% | 46.98% | $423K | 0.30% | — | HELD |
| 25 | LOOP | LONGEVERON INC | $0.72 | -2.04% | -52.93% | -92.06% | $361K | 0.26% | — | HELD |
Source: SEC EDGAR · accession 0002106181-26-000005. 13F discloses long positions only — shorts, foreign equities, and options are excluded.